GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (XSWX:BMY) » Definitions » Shiller PE Ratio

Bristol-Myers Squibb Co (XSWX:BMY) Shiller PE Ratio : (As of May. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Bristol-Myers Squibb Co Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Bristol-Myers Squibb Co Shiller PE Ratio Historical Data

The historical data trend for Bristol-Myers Squibb Co's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Shiller PE Ratio Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.35 48.49 43.84 43.29 26.98

Bristol-Myers Squibb Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.63 35.04 30.89 26.98 43.73

Competitive Comparison of Bristol-Myers Squibb Co's Shiller PE Ratio

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Shiller PE Ratio falls into.



Bristol-Myers Squibb Co Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Bristol-Myers Squibb Co's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Bristol-Myers Squibb Co's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/129.4194*129.4194
=0.000

Current CPI (Mar. 2024) = 129.4194.

Bristol-Myers Squibb Co Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.179 100.560 0.230
201409 0.403 100.428 0.519
201412 0.010 99.070 0.013
201503 0.696 99.621 0.904
201506 -0.075 100.684 -0.096
201509 0.408 100.392 0.526
201512 -0.080 99.792 -0.104
201603 0.697 100.470 0.898
201606 0.669 101.688 0.851
201609 0.701 101.861 0.891
201612 0.540 101.863 0.686
201703 0.941 102.862 1.184
201706 0.542 103.349 0.679
201709 0.491 104.136 0.610
201712 -1.392 104.011 -1.732
201803 0.863 105.290 1.061
201806 0.228 106.317 0.278
201809 1.123 106.507 1.365
201812 0.724 105.998 0.884
201903 1.041 107.251 1.256
201906 0.860 108.070 1.030
201909 0.822 108.329 0.982
201912 -0.540 108.420 -0.645
202003 -0.326 108.902 -0.387
202006 -0.038 108.767 -0.045
202009 0.750 109.815 0.884
202012 -3.953 109.897 -4.655
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 0.000 121.301 0.000
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000
202303 0.000 127.348 0.000
202306 0.000 128.729 0.000
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000
202403 0.000 129.419 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bristol-Myers Squibb Co  (XSWX:BMY) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Bristol-Myers Squibb Co Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co (XSWX:BMY) Business Description

Address
430 East 29th Street, 14th Floor, New York, NY, USA, 10016
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.